Concomitant immunosuppressive and immunomodulatory treatment
| Glucocorticoids | No of patients (%) | Dose/day (mg), mean (SD) | |||||
|---|---|---|---|---|---|---|---|
| ⩽14 days before IAS | 16 (100) | 80 (84) | |||||
| Start of IAS | 16 (100) | 117 (159) | |||||
| After 3 months | 16 (100) | 29 (17)* | |||||
| After 6 months | 11 (100) | 19 (13)* | |||||
| After 12 months | 11 (100) | 9 (2)* | |||||
| IVCP | No of patients (%) | Pulses | Cumulative dose (mg), mean (SD) | ||||
|---|---|---|---|---|---|---|---|
| 12–13 Months before IAS | 9 (56) | 7 (5) | 5493 (4055) | ||||
| ±3 Months from start of IAS | 9 (56) | 3 (1) | 5503 (3923) | ||||
| 3–6 Months after start of IAS | 1 (9) | 1 | 700 | ||||
| 6–12 Months after start of IAS | 0 (0) | 0 | 0 | ||||
| Time | Oral immunomodulation with: | ||||||
|---|---|---|---|---|---|---|---|
| AZA† | CQ† | CP† | MMF† | MTX† | None† | ||
| AZA, azathioprine; CQ, chloroquine; CP, cyclophosphamide by mouth; MMF, mycophenolate mofetil; MTX, methotrexate; IVCP, intravenous cyclophosphamide. | |||||||
| *Indicates a p<0.05; dosage of oral immunomodulation: AZA 100 mg/day, CQ 250 mg/day, MTX 25 mg/week, CP 100 mg/day, MMF 2 g/day; †No (%) of patients; chloroquine was used as monotherapy or as an adjunct (in ‡one patient before, ‡one patient at the start of IAS, and in §two patients during IAS). | |||||||
| ⩽1 Year before IAS | 2 (13) | 3 (19)‡ | 2 (13) | 0 (0) | 2 (13) | 8 (50) | |
| ⩽3 Months before IAS | 2 (13) | 1 (6) | 4 (25) | 0 (0) | 1 (6) | 8 (50) | |
| Start of IAS | 2 (13) | 2 (13)‡ | 4 (25) | 0 (0) | 1 (6) | 8 (50) | |
| After 3 months | 3 (19) | 4 (25) | 4 (25) | 1 (6) | 1 (6) | 5 (31) | |
| After 6 months | 2 (18) | 3 (27)§ | 2 (18) | 4 (36) | 0 (0) | 2 (18) | |
| After 12 months | 2 (18) | 3 (27)§ | 1 (9) | 5 (45) | 0 (0) | 2 (18) | |